Well, traditionally, patients who were node-negative at diagnosis still have a sentinel node biopsy after neoadjuvant therapy to check the axillary. Now, we are more and more trials testing whether we can safely skip that surgery in these patients. For example, we have the EURBREAST-01 in Europe, or the ASLAN and the OPTIMIST trials in Korea. They may include triple-negative and HER2-POSITIVE tumours that respond completely in the breast...
Well, traditionally, patients who were node-negative at diagnosis still have a sentinel node biopsy after neoadjuvant therapy to check the axillary. Now, we are more and more trials testing whether we can safely skip that surgery in these patients. For example, we have the EURBREAST-01 in Europe, or the ASLAN and the OPTIMIST trials in Korea. They may include triple-negative and HER2-POSITIVE tumours that respond completely in the breast. We wanted to know whether the inclusion criteria of these trials apply to real-world patients. So we looked at almost 6 ,000 patients from the USOMA database. is an European network of hospitals with 35 specialised breast units that meet strict quality standards. So these aren’t data from one centre or from a trial population. They reflect everyday practice in high-quality breast units across Europe. That makes the results very relevant to routine care. the results were consistent. With what the trials have shown so far. In triple-negative and HER2-POSITIVE patients with a complete response in the breast, residual disease in the axilla was very, very low, between 1 % and 2%. In other words, if we have skipped axillary surgery in these women, disease would have gone undetected in just one or two of every hundred. still waiting for the oncological results of these trials. But our data show that, in the real world, the patients who could avoid axillary surgery do meet the inclusion criteria of these studies. So, once the trial results arrive, they can be applied directly to patients in everyday practice and those patients will benefit. That means less surgery, fewer side effects such as arm swelling and better quality of life. That we move into a safer, less aggressive surgery. Near-juvenile therapy doesn’t compromise breast conservation and for some women, axillary surgery may soon be avoidable. The key is to be treated by a specialized multidisciplinary breast team.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.